Apellis Pharmaceuticals
Apellis Pharmaceuticals's Overview
Apellis Pharmaceuticals is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet medical need through inhibition of the complement cascade, a critical component of the immune system. The company is a leader in targeting C3, a central protein in this cascade, to develop transformative therapies for a broad range of debilitating conditions across ophthalmology, hematology, nephrology, and neurology.
Where is Apellis Pharmaceuticals's Headquarters?
HQ Function
Serves as the global corporate headquarters, housing executive leadership, research and development (R&D) laboratories, and key administrative functions that drive Apellis's overall strategy and operations.
Notable Features:
Modern office and state-of-the-art laboratory spaces designed to foster scientific innovation and collaboration. Located within the dynamic Greater Boston biotechnology hub, offering access to a rich ecosystem of talent, research institutions, and industry partners.
Work Culture:
Characterized by a strong emphasis on science, innovation, and a patient-centric mission. Apellis fosters a collaborative, fast-paced environment where employees are driven to develop breakthrough therapies for serious diseases.
HQ Significance:
The Waltham headquarters is pivotal for Apellis's R&D advancements, strategic decision-making, and global corporate governance. Its location in a prominent biotech cluster enhances talent recruitment, scientific collaborations, and industry engagement.
Values Reflected in HQ: The headquarters' design and operations aim to reflect Apellis's core values of scientific rigor, pioneering innovation, collaboration, and an unwavering commitment to improving patients' lives.
Location:
Apellis Pharmaceuticals maintains a significant global presence with key functions distributed across North America, Europe, and Australia. These functions include research and development, global manufacturing and supply chain management, clinical trial operations, commercial activities, medical affairs, and regulatory engagement. The company is strategically expanding its international footprint to deliver its C3-targeted therapies to patients with serious diseases worldwide.
Street Address:
100 Fifth Avenue
City:
Waltham
State/Province:
Massachusetts
Country:
USA
Apellis Pharmaceuticals's Global Presence
Crestwood, Kentucky/USA
Address: 4000 Apellis Way, Crestwood, KY 40014
Ensures the reliable manufacturing and supply of Apellis's therapies to meet patient needs globally, playing a key role in the company's operational backbone.
Zug, Switzerland
Address: Apellis Switzerland GmbH, Dammstrasse 21, CH-6300 Zug
Manages the launch, commercialization, and market access of Apellis's products across European countries and supports expansion into other international regions.
Sydney, New South Wales/Australia
Address: Apellis Australia Pty Ltd, Level 36, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000
Establishes and grows Apellis's presence in the Oceania region, ensuring patient access to its innovative treatments and engaging with local healthcare systems.
Buying Intent Signals for Apellis Pharmaceuticals
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Apellis Pharmaceuticals
As of April 2025, Apellis Pharmaceuticals' leadership includes:
Investors of Apellis Pharmaceuticals
Apellis Pharmaceuticals has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12 months, Apellis Pharmaceuticals has made strategic appointments and transitions within its executive leadership to support its growth and commercial objectives. Key changes include the appointment of a new Chief Commercial Officer, a new Chief Medical Officer for Ophthalmology, and internal promotions to Chief Operating Officer and a newly created Chief Innovation Officer role.
Departures
New Appointments:
Technology (Tech Stack) used by Apellis Pharmaceuticals
Discover the tools Apellis Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Apellis Pharmaceuticals Email Formats and Examples
Apellis Pharmaceuticals typically uses a standard corporate email format. The most commonly observed pattern is `firstname.lastname@apellis.com`. Variations such as `firstinitiallastname@apellis.com` may also exist but are less frequent.
firstname.lastname@apellis.com
Format
john.smith@apellis.com
Example
85%
Success rate
News and media
Apellis Pharmaceuticals Investor Relations • May 7, 2024
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
Apellis reported $134.7 million in Q1 2024 total U.S. net product revenue for SYFOVRE® (pegcetacoplan injection). The company highlighted continued strong demand with over 62,000 commercial vials and 22,000 samples distributed in the quarter, and ongoing progress in market access for the geographic atrophy treatment....more
Apellis Pharmaceuticals Press Release • May 21, 2024
Apellis and Sobi Report Positive Top-Line Results from Phase 3 VALIANT Study of Pegcetacoplan in Primary Immune Thrombocytopenia (ITP)
Apellis and Sobi announced that the Phase 3 VALIANT study of pegcetacoplan in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The study demonstrated a statistically significant improvement in platelet counts for patients treated with pegcetacoplan compared to placebo....more
Apellis Pharmaceuticals Press Release • January 3, 2024
Apellis Announces Key Leadership Appointments and Updates on 2024 Strategic Priorities
Apellis outlined its strategic priorities for 2024, emphasizing maximizing the SYFOVRE® launch, advancing its C3 pipeline including APL-1030 for neurological diseases, and strengthening its financial foundation. The company also announced key leadership appointments and promotions to drive these initiatives....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Apellis Pharmaceuticals, are just a search away.